Nymox Pharmaceutical Corporation (NYMX) announced Sunday that its experimental drug NX-1207, designed to treat prostate enlargement, did not meet pivotal endpoints in late-stage trials for the drug being run in the US.
Nymox Pharmaceutical Corporation (NYMX) announced Sunday that its experimental drug NX-1207, designed to treat prostate enlargement, did not meet pivotal endpoints in late-stage trials for the drug being run in the US.
Share this Article
Comment on this Article
Recommended
Please to comment